Third quarter earnings season is in full swing, and analysts expect S&P 500 companies grew their profits by 8% during the ...

Merck said on Tuesday that it has entered into an agreement to receive funds managed by Blackstone Life Sciences for $700 ...

Merck & Co Inc. (NYSE:MRK) is one of the best stocks to invest in, according to billionaire D.E. Shaw. On October 30, Merck & Co Inc.

The study will test the antibody-drug conjugate in combination with Keytruda in patients with HER2-overexpressing metastatic non-small cell lung cancer.

Phase 2 clinical trial underway with first patient dosed in October to support a clear path to Phase 3 based on previous alignment with FDA Patients randomized to either 10 or 20 mg/kg of muzastotug ...

Along with Verona, MSD has been adding to its post-Keytruda prospects with a string of acquisitions and licensing deals in ...

Phase 2 clinical trial underway with first patient dosed in October to support a clear path to Phase 3 based on previous alignment with FDA ...

The company's outlook for the rest of the year was rosier than in the previous quarter, when it announced a cost-cutting plan ...

Merck, which has claimed bragging rights as the maker of the world’s best-selling drug, Keytruda, since 2023, has officially ...

Merck & Co posted higher third-quarter revenue on Thursday, as growth from its blockbuster cancer drug Keytruda offset ...

Together, Mounjaro and Zepbound brought in $11.98 billion in the third quarter even with price decreases for the medicines.